{"id":7151,"date":"2019-12-24T15:41:28","date_gmt":"2019-12-24T10:11:28","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7151"},"modified":"2021-07-24T12:57:42","modified_gmt":"2021-07-24T07:27:42","slug":"recent-pharma-happenings-for-roche-sarepta-merck-allergan","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan","title":{"rendered":"Roche, Sarepta collaborates; FDA approval for Merck\u2019s Ervebo, and Allergan\u2019s Ubrelvy"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion.&nbsp;<\/strong><\/h2>\n\n\n\n<p>Roche has agreed to license in Sarepta\u2019s gene therapy \u2018SRP-9001\u2019 for <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market-insight-epidemiology-and-market-forecast\">Duchenne muscular dystrophy (DMD),<\/a> though which Roche will gain access to exclusive rights to it globally except in the US.&nbsp;<\/p>\n\n\n\n<p>As per the DelveInsight analysis, there were 4769 patients in the age group 8\u201313 years followed by 14\u2013the 19-year age group with 4726 patients in 2017 in the United States.<\/p>\n\n\n\n<p>The goal of <a href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/\">Duchenne Muscular Dystrophy (DMD) treatment<\/a> is to control the symptoms of DMD and related complications caused by severe progressive muscle weakness and loss to maximise the quality of life. Various therapies have been developed for treating DMD. However, companies are testing the potential of gene therapies to tackle DMD treatment challenges like the product gene size, the origin of dystrophin gene expression, transport effectiveness, and immunological rejection.<\/p>\n\n\n\n<p>Under the agreement, Roche will pay Sarepta an amount of USD 750 Million upfront, and remaining USD 400 million in stocks and equity. Furthermore, Sarepta on receiving regulatory and sales milestones will receive royalties on net sales.&nbsp;<\/p>\n\n\n\n<p>However, the companies have decided to share the developmental expenses equally. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The US FDA has given its recommendations to Merck\u2019s Ervebo vaccines for the prevention of Ebola virus disease (EVD).<\/strong><\/h2>\n\n\n\n<p>Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF) or simply Ebola, is caused by virus species <em>Zaire ebolavirus. <\/em>Ebola virus cases have a mortality rate of up to 90%. EVD cases are relatively rare in the USA, and recent outbreaks took place in Central and West Africa, near tropical rainforests.<\/p>\n\n\n\n<p>The vaccine is a single-dose injection and is bioengineered as a live, attenuated injection containing protein from the virus.&nbsp;<\/p>\n\n\n\n<p>Ebola virus disease is rare but severe and is contagious. EVD spreads to the healthy population through infected blood, secretions, fluids, and other body fluids of infected animals like a chimpanzee, gorilla, fruit bats, monkeys, forest antelopes and porcupines.<\/p>\n\n\n\n<p>The company has received the approval from the European Commission, and this is the second regulatory milestone Merck has achieved. However, Ervebo remains unapproved in the most affected areas, i.e., Africa. The company has filed for the approval to African regulators in collaboration with the African Vaccine Regulatory Forum. <br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The US FDA has approved Ubrelvy, a drug of Allergan, for the immediate treatment of migraine with or without aura in adults. <\/strong><\/h2>\n\n\n\n<p>The drug belongs to the class of oral calcitonin gene-related peptide receptor antagonists recommended for the acute <a href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market\">migraine <\/a>treatment.\u00a0<\/p>\n\n\n\n<p>As per the World Health Organization\u2019s disability rating, <a href=\"https:\/\/www.delveinsight.com\/blog\/a-new-era-for-migraine-treatment-and-cgrp-antibodies\/\">Migraine<\/a> is recognised as the 19th most common reason for disability and is three times more common in women. According to the US Centers for Disease Control, self-reported migraine prevalence in the United States increased by 60%, from 25.8 to 41 per 1000 person-years between 1981 and 1989.<\/p>\n\n\n\n<p>Ubrelvy is the first oral calcitonin gene-related peptide receptor (CGRP) and is not indicated for the preventive treatment of migraine. It is the first drug in the class of CGRP receptor antagonists approved for the acute treatment of migraine.<br><\/p>\n\n\n\n<p><br><\/p>\n\n\n<p><!--EndFragment--><\/p>","protected":false},"excerpt":{"rendered":"<p>Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion.&nbsp; Roche has agreed to license in Sarepta\u2019s gene therapy \u2018SRP-9001\u2019 for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive rights to it globally except in the US.&nbsp; As per the DelveInsight analysis, there were 4769 patients in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7152,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[70,17916,17917,17919,395,524,2581,17918],"industry":[17225],"therapeutic_areas":[17231,17245,17234],"class_list":["post-7151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-allergan","tag-duchenne-muscular-dystrophy-treatment","tag-ebola-virus-disease","tag-ervebo-vaccines","tag-merck","tag-roche","tag-sarepta-therapeutics","tag-ubrelvy","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Roche, Sarepta collaborates; FDA approval for Merck\u2019s Ervebo<\/title>\n<meta name=\"description\" content=\"Roche has agreed to license in Sarepta\u2019s gene therapy \u2018SRP-9001\u2019 for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche, Sarepta collaborates; FDA approval for Merck\u2019s Ervebo\" \/>\n<meta property=\"og:description\" content=\"Roche has agreed to license in Sarepta\u2019s gene therapy \u2018SRP-9001\u2019 for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-24T10:11:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/24154028\/news-24.12.2019.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche, Sarepta collaborates; FDA approval for Merck\u2019s Ervebo","description":"Roche has agreed to license in Sarepta\u2019s gene therapy \u2018SRP-9001\u2019 for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan","og_locale":"en_US","og_type":"article","og_title":"Roche, Sarepta collaborates; FDA approval for Merck\u2019s Ervebo","og_description":"Roche has agreed to license in Sarepta\u2019s gene therapy \u2018SRP-9001\u2019 for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-12-24T10:11:28+00:00","article_modified_time":"2021-07-24T07:27:42+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/24154028\/news-24.12.2019.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan","name":"Roche, Sarepta collaborates; FDA approval for Merck\u2019s Ervebo","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/24154028\/news-24.12.2019.jpg","datePublished":"2019-12-24T10:11:28+00:00","dateModified":"2021-07-24T07:27:42+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Roche has agreed to license in Sarepta\u2019s gene therapy \u2018SRP-9001\u2019 for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-roche-sarepta-merck-allergan#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/24154028\/news-24.12.2019.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/24154028\/news-24.12.2019.jpg","width":772,"height":482,"caption":"pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/24154028\/news-24.12.2019-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ebola Virus Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ervebo Vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sarepta Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ubrelvy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Duchenne Muscular Dystrophy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Ebola Virus Disease<\/span>","<span class=\"advgb-post-tax-term\">Ervebo Vaccines<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Sarepta Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Ubrelvy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 24, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 24, 2019 3:41 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7151"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7151\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7152"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7151"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7151"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}